Treatment of periodic leg movement disorder and restless leg syndrome with talipexole
Open Access
- 1 April 1999
- journal article
- research article
- Published by Wiley in Psychiatry and Clinical Neurosciences
- Vol. 53 (2) , 283-285
- https://doi.org/10.1046/j.1440-1819.1999.00522.x
Abstract
In order to investigate the bedtime dose of talipexole, a D2 and α2 stimulant, on patients with periodic leg movement disorder (PLMD) and restless leg syndrome (RLS), we made a comparison of polysomnographic findings and subjective symptom ratings before and during 4 weeks of the treatment on five cases with RLS and PLMD. A significant decrease in both the frequencies of periodic leg movements and subjective symptom ratings and significant improvement of sleep composition were recognized during the treatment. We speculate that the combination of the agonistic action of D2 and α2 receptor with the drug might not only suppress PLMD and RLS but also improve sleep quality.Keywords
This publication has 5 references indexed in Scilit:
- Management of Insomniac PatientsSleep, 1996
- Single photon emission tomography (SPET) imaging of dopamine D2 receptors in the course of dopamine replacement therapy in patients with nocturnal myoclonus syndrome (NMS)Journal Of Neural Transmission-Parkinsons Disease and Dementia Section, 1995
- Restless Legs Syndrome and Periodic Movements in SleepClinical Neuropharmacology, 1986
- Sleep Disruption in the Course of Chronic Levodopa TherapyClinical Neuropharmacology, 1982
- Periodic movements in sleep (nocturnal myoclonus): Relation to sleep disordersAnnals of Neurology, 1980